{"contentid": 487968, "importid": NaN, "name": "US FDA tightens ship on Accelerated Approval scheme", "introduction": "A third pharma major in as many weeks has voluntarily withdrawn from an immuno-oncology indication, as the US regulator toughens its stance towards Accelerated Approvals.", "content": "<p>A third pharma major in as many weeks has voluntarily withdrawn from an immuno-oncology indication, as the US regulator toughens its stance towards Accelerated Approvals.</p>\n<p>The US indication in question is for Tecentriq (atezolizumab), in prior-platinum treated metastatic urothelial carcinoma.</p>\n<p>Swiss cancer giant Roche (ROG: SIX) was granted an Accelerated Approval for these patients in 2016, on the basis of results from the IMvigor210 study.</p>\n<p>It is not an area in which the product has a major impact at present, and the withdrawal does not affect other approved indications for the checkpoint blocker.</p>\n<p>Global Tecentriq sales for 2020 came in at 2.7 billion Swiss francs ($2.9 billion), an increase of 55% from the year before.</p>\n<h2>\"Industry-wide evaluation\"</h2>\n<p>Roche&rsquo;s nod for Tecentriq in bladder cancer is just one of a range of Accelerated Approvals which have not been withdrawn by the FDA, despite a lack of confirmatory data.</p>\n<p>That now appears to be changing, with Merck &amp; Co (NYSE: MRK) referring in a statement to an \"industry-wide evaluation\" on the part of the US regulator, examining Accelerated Approvals which have not met post-marketing requirements.</p>\n<p>Last week Merck said it would stop marketing Keytruda (pembrolizumab) as a later-line option for certain people with small cell lung cancer (SCLC).</p>\n<p>That decision came after AstraZeneca (LSE: AZN) stopped selling Imfinzi (durvalumab) as a later-line metastatic bladder cancer option. In late 2020, Bristol Myers Squibb (NYSE: BMY) withdrew its checkpoint blocker, Opdivo (nivolumab), in SCLC.</p>\n<p>Roche chief medical officer Levi Garraway said: &ldquo;While the withdrawal of Tecentriq for prior-platinum treated bladder cancer is disappointing, Tecentriq continues to demonstrate benefits across multiple cancer types and therefore remains a meaningful treatment option for many patients.&rdquo;</p>", "date": "2021-03-08 10:33:00", "meta_title": NaN, "meta_keywords": "Accelerated, cancer, Approvals, Tecentriq, indication, major, regulator, withdrawn, Approval, scheme, ship, tightens, voluntarily, weeks, immuno-oncology", "meta_description": "A third pharma major in as many weeks has voluntarily withdrawn from an immuno-oncology indication, as the US regulator toughens its stance towards Accelerated ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-08 10:03:10", "updated": "2021-03-08 10:35:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/us-fda-tightens-ship-on-accelerated-approval-scheme", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "fda_big.jpg", "image2id": "fda_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Focus On, Regulation, Research, US FDA", "geography_tag": "Switzerland, USA", "company_tag": "AstraZeneca, FDA, Merck & Co, Roche", "drug_tag": "Imfinzi, Keytruda, Tecentriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-08 10:33:00"}